Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $7.6 million.

  • Axsome Therapeutics' Gains from Investment Securities fell 10.25% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 10.25%. This contributed to the annual value of $8.4 million for FY2024, which is 0.27% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Gains from Investment Securities is $7.6 million, which was up 2,429.21% from $300,000 recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Gains from Investment Securities high stood at $23.9 million for Q1 2025, and its period low was $38,000 during Q4 2023.
  • For the 3-year period, Axsome Therapeutics' Gains from Investment Securities averaged around $6.9 million, with its median value being $7.9 million (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 1,332.82% in 2023, then crashed by 96.64% in 2025.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Gains from Investment Securities stood at $739,000 in 2022, then tumbled by 94.86% to $38,000 in 2023, then surged by 1,123.68% to $465,000 in 2024, then fell by 10.25% to $7.6 million in 2025.
  • Its Gains from Investment Securities stands at $7.6 million for Q3 2025, versus $300,000 for Q2 2025 and $23.9 million for Q1 2025.